Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Risselada, A
Tekstra, J
Teng, Y K
Welsing, P M J
Breedveld, F
van Laar, J M
and
Bijlsma, J W J
2010.
Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
Annals of the Rheumatic Diseases,
Vol. 69,
Issue. 10,
p.
1891.
Merkesdal, Sonja
Kirchhoff, Timm
Wolka, Diane
Ladinek, Gunter
Kielhorn, Adrian
and
Rubbert-Roth, Andrea
2010.
Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
The European Journal of Health Economics,
Vol. 11,
Issue. 1,
p.
95.
Adams, Roisin
Walsh, Cathal
Veale, Douglas
Bresnihan, Barry
FitzGerald, Oliver
and
Barry, Michael
2010.
Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis.
PharmacoEconomics,
Vol. 28,
Issue. 6,
p.
477.
Fautrel, Bruno
Verstappen, Suzanne M.M.
and
Boonen, Annelies
2011.
Economic consequences and potential benefits.
Best Practice & Research Clinical Rheumatology,
Vol. 25,
Issue. 4,
p.
607.
Tran-Duy, An
Boonen, Annelies
van de Laar, Mart A F J
Franke, Angelinus C
and
Severens, Johan L
2011.
A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
Annals of the Rheumatic Diseases,
Vol. 70,
Issue. 12,
p.
2111.
Benucci, Maurizio
Saviola, Gianantonio
Baiardi, Paola
and
Manfredi, Mariangela
2011.
Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life.
Rheumatology International,
Vol. 31,
Issue. 11,
p.
1465.
Adams, Roisin
Craig, Benjamin M.
Walsh, Cathal D.
Veale, Douglas J.
Bresnihan, Barry
FitzGerald, Oliver
and
Barry, Michael
2011.
The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort.
Value in Health,
Vol. 14,
Issue. 6,
p.
921.
Buch, Maya H
Smolen, Josef S
Betteridge, Neil
Breedveld, Ferdinand C
Burmester, Gerd
Dörner, Thomas
Ferraccioli, Gianfranco
Gottenberg, Jacques-Eric
Isaacs, John
Kvien, Tore K
Mariette, Xavier
Martin-Mola, Emilio
Pavelka, Karel
Tak, Paul P
van der Heijde, Desiree
van Vollenhoven, Ronald F
and
Emery, Paul
2011.
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases,
Vol. 70,
Issue. 6,
p.
909.
Marra, Carlo A.
Bansback, Nick
Anis, Aslam H.
and
Shojania, Kamran
2011.
Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.
Clinical Rheumatology,
Vol. 30,
Issue. S1,
p.
9.
Tsao, Nicole W.
Bansback, Nick J.
Shojania, Kam
and
Marra, Carlo A.
2012.
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Best Practice & Research Clinical Rheumatology,
Vol. 26,
Issue. 5,
p.
659.
Fautrel, Bruno
and
Gaujoux-Viala, Cécile
2012.
Aspects médico-économiques de la polyarthrite rhumatoïde.
Bulletin de l'Académie Nationale de Médecine,
Vol. 196,
Issue. 7,
p.
1295.
Hernández Alava, Mónica
Wailoo, Allan J.
and
Ara, Roberta
2012.
Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values.
Value in Health,
Vol. 15,
Issue. 3,
p.
550.
Hernández Alava, Mónica
Wailoo, Allan
Wolfe, Fred
and
Michaud, Kaleb
2013.
The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.
Rheumatology,
Vol. 52,
Issue. 5,
p.
944.
Linde, Louise
Sørensen, Jan
Østergaard, Mikkel
and
Hetland, Merete Lund
2013.
Gain in Quality-adjusted Life-years in Patients with Rheumatoid Arthritis During 1 Year of Biological Therapy: A Prospective Study in Clinical Practice.
The Journal of Rheumatology,
Vol. 40,
Issue. 9,
p.
1479.
Sullivan, Sean D.
Alfonso-Cristancho, Rafael
Carlson, Josh
Mallya, Usha
and
Ringold, Sarah
2013.
Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.
Journal of Medical Economics,
Vol. 16,
Issue. 3,
p.
391.
Standfield, Lachlan
Comans, Tracy
and
Scuffham, Paul
2014.
MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISON.
International Journal of Technology Assessment in Health Care,
Vol. 30,
Issue. 2,
p.
165.
van Haalen, H. G. M.
Severens, J. L.
Tran-Duy, A.
and
Boonen, A.
2014.
How to Select the Right Cost-Effectiveness Model?.
PharmacoEconomics,
Vol. 32,
Issue. 5,
p.
429.
Scholz, Stefan
and
Mittendorf, Thomas
2014.
Modeling rheumatoid arthritis using different techniques - a review of model construction and results.
Health Economics Review,
Vol. 4,
Issue. 1,
Pennington, Becky
and
Davis, Sarah
2014.
Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results.
Value in Health,
Vol. 17,
Issue. 8,
p.
762.
Karnon, Jonathan
and
Haji Ali Afzali, Hossein
2014.
When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES.
PharmacoEconomics,
Vol. 32,
Issue. 6,
p.
547.